Cargando…

Correction: Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549601/ https://www.ncbi.nlm.nih.gov/pubmed/31152048 http://dx.doi.org/10.1136/bmjopen-2017-015904corr1

Ejemplares similares

Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial
por: Hutt, Emilie, et al.
Publicado: (2018)

Correction to: Prognostic nomogram for overall survival in upper urinary tract urothelial carcinoma (UTUC) patients treated with chemotherapy: a SEER-based retrospective cohort study
por: Tian, Cong, et al.
Publicado: (2023)

Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2021)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer
por: Shimokawa, Mototsugu, et al.
Publicado: (2018)

Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial
por: Oostendorp, Linda J. M., et al.
Publicado: (2017)

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
por: Okines, A, et al.
Publicado: (2009)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
por: Ledermann, J.A., et al.
Publicado: (2021)

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2022)

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer
por: Tobias, Claire J., et al.
Publicado: (2020)

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Hoeh, Benedikt, et al.
Publicado: (2021)

Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients
por: Tappero, Stefano, et al.
Publicado: (2022)

Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Publicado: (2020)

The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer
por: Zainal Abidin, Mohd Naqib, et al.
Publicado: (2022)

The Impact of Palliative Chemotherapy on the Survival of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
por: Schad, Friedemann, et al.
Publicado: (2022)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Publicado: (2020)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

A Case of Upper Gastrointestinal Bleeding Due to Metastatic High-Grade B-Cell Lymphoma Successfully Treated With Chemotherapy
por: Tanner, Samuel, et al.
Publicado: (2022)

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
por: Chen, Hao, et al.
Publicado: (2020)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation
por: Fujisaka, Y, et al.
Publicado: (2011)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Correction: Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy
Publicado: (2014)

Correction: Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy
Publicado: (2014)

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
por: Hong, Shaodong, et al.
Publicado: (2021)

Correction to: Prognostic significance of serum CA125 in the overall management for patients with gastrointestinal stromal tumors
por: Sui, Chao, et al.
Publicado: (2023)

Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC
por: Faoro, Lisa, et al.
Publicado: (2023)

Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma
por: Liao, Wenjun, et al.
Publicado: (2021)

Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer
por: Lee, Shu‐Hui, et al.
Publicado: (2019)

Correction to: Selected nasogastric lavage in patients with nonvariceal upper gastrointestinal bleeding
por: Gong, Eun Jeong, et al.
Publicado: (2021)

Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
Publicado: (2020)

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Publicado: (2023)

Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial
por: Curran, Desmond, et al.
Publicado: (2009)

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
por: Reck, M., et al.
Publicado: (2010)

Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
por: Colagrande, S., et al.
Publicado: (2020)

Palliation of Brain Metastases: Analysis of Prognostic Factors Affecting Overall Survival
por: Rastogi, Kartick, et al.
Publicado: (2018)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l55io2qgf2424mf35gbmd4p441